Effect of Plantago major on nonalcoholic fatty liver disease

Phase 2

Recruiting

• Conditions: on Alcoholic Fatty Liver Disease.; Non Alcoholic Fatty Liver Disease; K76-0

• Registration Number: IRCT20191006044993N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 December 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Sono graphic report of Grade 1 and 2 fatty liver
Increase in ALT> 40
Increase in AST>38
Ages 12 to 80 years

Exclusion Criteria

The patient's unwillingness to participate in the scheme
Pregnancy & lactation
Anti coagulant drugs consumption
Thyroid diseases
Spleen diseases
Cirrhosis ,viral hepatitis and obstructive liver disese
Treated dyslipidemia
Overt Diabetes mellitus
Lung diseases
Taking any medication that affects liver metabolism and enzymes, including oral contraceptives, corticosteroids, salazines, etc.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comprison of the Plantago major seed with Placebo on ALT enzyme(Alanin trasaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Onset, 6th and 12th week of study.(End of study). Method of measurement: Hitachi 912 instrument.;Comprison of the Plantago major seed with Placebo on AST enzyme(Aspartate transaminase) in Non Alcoholic Fatty Liver Disease (NAFLD). Timepoint: Liver enzymes measurement at baseline, 6th and 12th weeks (end of study). Method of measurement: Hitachi 912 instrument.